Epinephrine

The FDA approved ARS Pharmaceuticals’ neffy epinephrine nasal spray for emergency allergic reactions in children and adults weighing at least 66 pounds.

Our political system ensures that everyone throughout the country has representation, Melinda M. Rathkopf, MD, MBA, told Healio. Leveraging that representation is essential when physicians need to advocate for their patients and themselves.

Advocates were pleased to learn about the FDA’s approval of ARS Pharmaceuticals’ neffy epinephrine nasal spray, which may have a significant impact on the safety and quality of life of families with allergy.

The FDA has approved neffy epinephrine nasal spray for emergency treatment of Type 1 allergic reactions, including anaphylaxis, in pediatric and adult individuals weighing at least 66 pounds.

Giving young children an epinephrine autoinjection can be a positive and confidence-boosting experience for families, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

A crossover study revealed that dry powder epinephrine administered via nasal spray yielded drug exposures equal to or higher than those provided by autoinjectors in a canine model.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended marketing authorization of ARS Pharmaceuticals’ EURneffy epinephrine nasal spray in the European Union, according to a press release.

A dry powder epinephrine delivered via a nasal spray yielded drug exposures that were equal to or higher than those achieved through autoinjector in a canine model, according to the results of a study performed by Belhaven Biopharma.

An epinephrine nasal spray is closer to approval in Europe, according to a press release from ARS Pharmaceuticals.

Patients with nasal congestion experienced enhanced absorption of epinephrine when it was administered via nasal spray compared with intramuscular administration, according to a study published in Annals of Allergy, Asthma & Immunology.